Communiqués AegirBio AB

Actions

AEGIR

SE0014401121

Marché Fermé - Nasdaq Stockholm Autres places de cotation 18:00:00 28/06/2024			Varia. 5j.	Varia. 1 janv.
0,478 ^SEK	+11,29 %		+4,37 %	-59,15 %

04/06	La société suédoise AegirBio va changer de nom pour devenir MagnOral	MT
17/05	AegirBio AB (publ) publie ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

AegirBio AB has received payment of Tranche 2 of SEK 5.00 million from Atlas Special Opportunities, LLC	27/06	AQ
AegirBio receives second milestone payment under RadX NIH	11/06	AQ
AegirBio announces strategic name change to MagnOral AB	04/06	AQ
AegirBio AB carries out previously announced directed share issue of 5,175,374 shares corresponding to approximately SEK 2.54 million to Atlas Special Opportunities and calls for payment of Tranche 2	30/05	AQ
AegirBio's CEO Marco Witteveen to Attend SalivaDirect's 3rd Annual Conference in Washington, DC, June 5-7, 2024	29/05	AQ
AEGIRBIO AB SUCCESSFULLY COMPLETES AN ADDITIONAL MILESTONE OF RADx® TECH PROGRAM	21/05	AQ
AEGIRBIO study published in Multiple Sclerosis and Related Disorders journal	16/05	AQ
AegirBio AB calls for payment of Tranche 1 of SEK 7.50 million and intends to carry out a directed set-off issue of 5,175,374 shares to Atlas Special Opportunities, LLC	13/05	AQ
AEGIRBIO Receives Milestone Payment under RadX NIH	08/05	AQ
AEGIRBIO AB ADVANCES FURTHER WITH "ACCESSIBILITY" MILESTONE COMPLETION IN RADx® TECH PROGRAM	30/04	AQ
AegirBio AB's subsidiary initiates arbitration against Salofa Oy	18/04	AQ
AegirBio's chairman has announced his intention to leave the board of directors	09/04	AQ
AegirBio enters into a conditional agreement on a MSEK 45 loan facility with Atlas Special Opportunities and an agreement to amend the outstanding convertible bonds, subject to EGM approval	09/04	AQ
Aegirbio Expands Oral Health Scientific Advisory Board with Professor Iain L.C. Chapple	27/02	AQ
Renowned Gastroenterologist, Dr. Adam S. Cheifetz, Joins AegirBio's Scientific Advisory Board	24/01	AQ
AegirBio AB: Atlas Special Opportunities, LLC calls for partial conversion of outstanding convertible bonds to a nominal amount of MSEK 5.00	20/12	AQ
AegirBio AB Receives $239,547 award from the National Institutes of Health RADx Tech Program	01/11	AQ
AegirBio focuses on RadX project, will not uphold CE-markings for the MagniaReader TDM tests	01/11	AQ
Interview with AegirBio CEO Mr Marco Witteveen	30/10/23	AQ
AegirBio promotes Dr. Vasiliki Fragkou to Chief Operating Officer from November 1, 2023.	09/10/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués AegirBio AB

Actions

AEGIR

SE0014401121

Communiqués

Filtres